Physician profile
Joel Katz
NPI 1558475913
$7,166.20
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,337 · 2020: $1,201 · 2021: $2,419 · 2022: $2,139 · 2023: $69.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $69.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $69.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,758.56 | 2019-2023 | Symbicort |
| Csl Behring | $841.47 | 2019-2023 | Haegarda |
| Glaxosmithkline, LLC. | $662.78 | 2019-2023 | Nucala |
| Kaleo, INC. | $472.84 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.52 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $309.12 | 2020-2022 | |
| Genzyme Corporation | $298.10 | 2019-2022 | |
| Optinose US, INC. | $286.92 | 2019-2022 | |
| Pfizer INC. | $277.69 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $245.13 | 2019-2022 | |
| Shire North American Group INC | $231.29 | 2019 | |
| Amgen INC. | $229.06 | 2021-2022 | |
| Octapharma USA, INC. | $191.54 | 2019-2022 | |
| Pharming Healthcare, INC. | $176.53 | 2019-2022 | |
| Covis Pharma Gmbh | $138.08 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $114.54 | 2021-2022 | |
| Incyte Corporation | $106.32 | 2021-2022 | |
| Abbvie INC. | $81.24 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $76.67 | 2021 | |
| Merck Sharp & Dohme LLC | $75.00 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $49.04 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $48.62 | 2022 | |
| Leo Pharma INC. | $38.93 | 2022 | |
| Aimmune Therapeutics, INC. | $27.36 | 2022 | |
| Grifols USA, LLC | $25.66 | 2021 | |
| Bio Products Laboratory USA, INC. | $20.90 | 2019 | |
| Genentech USA, INC. | $20.47 | 2019 | |
| Circassia INC. | $17.45 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $15.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.